TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

PET radiomics vs IPI risk score model performance for outcome prediction in de novo DLBCL

By Quintina Dawson

Share:

Sep 11, 2023

Learning objective: After reading this article, learners will be able to cite a new clinical development in lymphoma.


The Lymphoma Hub is excited to present a visual abstract representing key data externally validating the 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) model and comparing its model performance with the International Prognostic Index model. We have previously reported on the prognostic value of 18F-FDG–PET metabolic heterogeneity in DLBCL after first-line immunochemotherapy.


 

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content